Mercer Global Advisors Inc. ADV Purchases 10,666 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mercer Global Advisors Inc. ADV increased its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 110.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,345 shares of the medical device company's stock after buying an additional 10,666 shares during the period. Mercer Global Advisors Inc. ADV's holdings in DexCom were worth $1,582,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in DXCM. Nordea Investment Management AB increased its stake in shares of DexCom by 2.8% during the 4th quarter. Nordea Investment Management AB now owns 80,590 shares of the medical device company's stock worth $6,271,000 after purchasing an additional 2,183 shares during the last quarter. First Hawaiian Bank increased its position in DexCom by 556.1% during the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock worth $1,801,000 after buying an additional 19,629 shares during the last quarter. Watts Gwilliam & Co. LLC acquired a new position in DexCom during the fourth quarter worth $3,334,000. Czech National Bank raised its holdings in DexCom by 3.7% during the fourth quarter. Czech National Bank now owns 84,689 shares of the medical device company's stock valued at $6,586,000 after buying an additional 3,057 shares in the last quarter. Finally, Capital Investment Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter worth about $206,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. The trade was a 4.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,926 shares of company stock worth $4,734,384. Insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DXCM. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and raised their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley lifted their price target on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Citigroup upped their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Canaccord Genuity Group raised their target price on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Barclays boosted their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $98.11.

DexCom Price Performance

Shares of DXCM traded down $0.68 during mid-day trading on Friday, reaching $84.66. The company had a trading volume of 3,348,982 shares, compared to its average volume of 4,331,690. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company's 50-day moving average is $71.08 and its 200-day moving average is $77.20. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $132.26. The company has a market capitalization of $33.20 billion, a P/E ratio of 59.20, a P/E/G ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the company posted $0.32 EPS. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.